Tickers

1. Composite Trajectory Verdict

For a pre-revenue, clinical-stage biopharmaceutical company, the cash flow statement and balance sheet carry the most weight because they determine the runway to advance pemvidutide through Phase 3 and other trials, while the income statement primarily reflects the timing of R&D spend.

Composite Trajectory: Mixed

The annual income statement shows improvement (FY2025 net loss narrowed 7% to $88.1M from $95.1M in FY2024), but the quarterly trend shows deterioration (Q2 2026 YTD net loss widened 9% to $45.4M from $41.7M in Q2 2025 YTD; Q1 2026 net loss widened to $22.6M from $19.6M in Q1 2025). Cash generation is improving dramatically: the cash/investment position grew to $518.6M at June 30, 2026 from $273.5M at December 31, 2025, fueled by $289.5M in financing inflows in the first half of 2026. The balance sheet is strengthening in liquidity (cash+marketable securities up 90% in six months) and equity (stockholders' equity up 111% to $474.2M), though leverage appeared via a $35M term loan and dilution accelerated (shares outstanding up 75% in six months).

2. Red Flags

• Quarterly operating losses widening despite annual improvement: Q2 2026 YTD loss from operations widened 13% to $50.5M from $44.7M in Q2 2025 YTD, and Q1 2026 loss from operations was $24.2M (implied) vs $18.8M in Q1 2025 (10-Q Q2 2026, Consolidated Statements of Operations; 10-Q Q1 2026, Consolidated Statements of Changes in Stockholders' Equity)
• G&A expense rising consistently: +34% annually (FY2025 $28.1M vs FY2024 $21.0M) and +34% in Q2 2026 YTD ($15.6M vs $11.7M) (10-K FY2025, MD&A; 10-Q Q2 2026, MD&A)
• Term loan interest expense accelerating: $1.6M in FY2025 (first partial year) vs $9K in FY2024; $2.2M in Q2 2026 YTD vs $0.3M in Q2 2025 YTD (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, Consolidated Statements of Operations)
• Impairment charges for headquarters relocation: $1.5M recognized in H1 2026 for lease ROU asset and leasehold improvements (10-Q Q2 2026, Consolidated Statements of Cash Flows)
• Heavy reliance on equity financing with rapid dilution: Shares outstanding increased from 110.9M at Dec 31, 2025 to 194.5M at June 30, 2026 (+75% in six months); FY2025 saw a 53% increase from 72.4M (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets)
• Accumulated deficit growing rapidly: $694.9M at June 30, 2026 vs $649.5M at Dec 31, 2025 vs $561.4M at Dec 31, 2024 (10-Q Q2 2026, Consolidated Balance Sheets; 10-K FY2025, Consolidated Balance Sheets)
• No product revenue: Revenue remains negligible ($41K in FY2025, $0 in H1 2026) (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, Consolidated Statements of Operations)
• Securities litigation: Class action and derivative suits filed in Q3 2025 (voluntarily dismissed without prejudice) (10-K FY2025, Note 14)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show improvement: FY2025 net loss narrowed 7% to $88.1M from $95.1M in FY2024, driven by a 19% decrease in R&D expense ($66.4M vs $82.2M) as the IMPACT Phase 2b trial completed enrollment, partially offset by a 34% increase in G&A ($28.1M vs $21.0M) (10-K FY2025, Consolidated Statements of Operations). Quarterly results show deterioration: Q2 2026 YTD net loss widened 9% to $45.4M from $41.7M in Q2 2025 YTD, with R&D up 5% ($34.8M vs $33.1M) and G&A up 34% ($15.6M vs $11.7M) as ALD/AUD trials progressed and PERFORMA Phase 3 startup costs began (10-Q Q2 2026, Consolidated Statements of Operations). Q1 2026 net loss of $22.6M also exceeded Q1 2025's $19.6M (10-Q Q1 2026, Consolidated Statements of Changes in Stockholders' Equity). Net loss per share improved annually ($1.00 vs $1.34) and quarterly ($0.29 vs $0.53 YTD) due to share count growth.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

The liquidity position has strengthened substantially. Total cash, cash equivalents, and marketable securities (short-term + long-term) rose to $518.6M at June 30, 2026 from $273.5M at December 31, 2025 (10-Q Q2 2026, Consolidated Balance Sheets; 10-K FY2025, Liquidity and Capital Resources). Financing inflows surged: H1 2026 net financing cash flow was $289.5M (April 2026 offering $211.1M, January 2026 RDO $70.3M, ATM $8.7M) vs $86.4M in H1 2025 (10-Q Q2 2026, Consolidated Statements of Cash Flows). FY2025 financing cash flow was $206.8M vs $10.0M in FY2024 (10-K FY2025, Consolidated Statements of Cash Flows). Operating cash burn worsened in H1 2026 to $45.2M from $36.2M in H1 2025, but improved annually to $67.5M in FY2025 from $79.8M in FY2024 (10-Q Q2 2026, Consolidated Statements of Cash Flows; 10-K FY2025, Consolidated Statements of Cash Flows). Management states cash on hand is sufficient for at least 12 months from each filing date.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets nearly doubled in six months to $527.2M at June 30, 2026 from $279.9M at December 31, 2025, driven by the investment portfolio (10-Q Q2 2026, Consolidated Balance Sheets; 10-K FY2025, Consolidated Balance Sheets). Stockholders' equity more than doubled to $474.2M from $224.9M over the same period, reflecting $281.4M in net proceeds from the April 2026 offering and January 2026 RDO (10-Q Q2 2026, Consolidated Statements of Changes in Stockholders' Equity). The term loan remains at $35M principal ($34.7M net) with no current portion due; maturity is January 2029 (10-Q Q2 2026, Note 5). Current liabilities decreased slightly to $12.5M from $15.0M. Accumulated deficit grew to $694.9M from $649.5M. The debt-to-equity ratio remains low (term loan ~7% of equity), and the company holds no revenue-generating assets.

6. Data Gaps

• Q3 2025 financial statements (income statement, cash flows, balance sheet) — only MD&A provided in the 10-Q filed 2025-11-06
• Q4 2025 standalone quarterly figures (only full-year FY2025 available in 10-K)
• Q3 2026 and Q4 2026 periods (not yet filed)
• Quarterly R&D breakdown by program (MASH, ALD, AUD) for Q1 2026 and Q3 2025 (only provided for Q2 2026 and FY2025 in MD&A)
• Quarterly stock-based compensation expense allocation (R&D vs G&A) for Q1 2026 and Q3 2025
• Detailed cash flow from operations for Q3 2025 and Q4 2025